Page last updated: 2024-08-24

topotecan and th 302

topotecan has been researched along with th 302 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baruchel, S; Kumar, S; Marrano, P; Thorner, P; Wu, B; Zhang, L	1

Other Studies

1 other study(ies) available for topotecan and th 302

Article	Year
Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11 Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays	2016

Article

Year

Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 06-01, Volume: 22, Issue:11

Topics: Activation, Metabolic; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Inhibitory Concentration 50; Mice, Inbred NOD; Mice, SCID; Neuroblastoma; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Rhabdomyosarcoma; Topotecan; Xenograft Model Antitumor Assays

2016